Thrombopoietin-Producing Hepatocellular Carcinoma

Ryu, Tomiko; Nishimura, Satoshi; Miura, Hideaki; Yamada, Hideaki; Morita, Hirohisa; Miyazaki, Hiroshi; Kitamura, Shigehiro; Miura, Yasusada; Saito, Toshikazu

doi:10.2169/internalmedicine.42.730

Cited by 21 publications

(14 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8,17,18 The reasons are unclear but one possibility is production of a thrombopoietic factor by HCC cells. 19 These observations require further study.…”

Section: Discussionmentioning

confidence: 97%

Survival in Asian Americans After Treatments for Hepatocellular Carcinoma

Tong

Chavalitdhamrong²,

Lu³

et al. 2010

Journal of Clinical Gastroenterology

View full text Add to dashboard Cite

show abstract

“…8,17,18 The reasons are unclear but one possibility is production of a thrombopoietic factor by HCC cells. 19 These observations require further study.…”

Section: Discussionmentioning

confidence: 97%

Survival in Asian Americans After Treatments for Hepatocellular Carcinoma

Tong

Chavalitdhamrong²,

Lu³

et al. 2010

Journal of Clinical Gastroenterology

View full text Add to dashboard Cite

show abstract

“…Patients with HCVrelated HCC had a higher prevalence of thrombocytopenia than patients with HBV-related HCC (63% vs. 42%). Although a patient with thrombopoietin-produ- cing HCC has been reported, 34 the significance of this finding is limited. The results from Pilot Study 3 indicated that the prevalence of thrombocytopenia was slightly greater in patients with chronic HCV infection than in patients with chronic HBV infection (26.7% vs. 5.6%).…”

Section: Discussionmentioning

confidence: 99%

Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high‐risk for hepatocellular carcinoma

Wang

Liu

et al. 2006

Cancer

148

131

View full text Add to dashboard Cite

BACKGROUND.The objective of this study was to examine the usefulness of platelet counts in the diagnosis of cirrhosis and for identifying high‐risk individuals in a community‐based hepatocellular carcinoma (HCC) screening program.METHODS.Pilot Study 1 determined the correlation between platelet counts and pathologic hepatic fibrosis scores among individuals with chronic hepatitis B virus (HBV) infection (n = 122 patients) and hepatitis C virus (HCV) infection (n = 244 patients). Pilot Study 2 investigated proportions of individuals with thrombocytopenia (<150 × 103/mm3) among patients with HCC (n = 4042 patients). Pilot Study 3 demonstrated the correlation between platelet counts and ultrasonographic (US) parenchyma scores among anti‐HCV‐positive individuals (n = 75 patients). The core study was a 2‐stage, community‐based screening for HCC among residents age 40 years or older in townships with a high prevalence of anti‐HCV (n = 4616 individuals) and in townships with a low prevalence of anti‐HCV (n = 1694 individuals). Patients with thrombocytopenia were identified for US and α‐fetoprotein screening.RESULTS.Among the individuals who were positive for anti‐HCV, platelet counts decreased according to increased pathologic fibrosis scores or US scores for liver parenchyma disease: The best cutoff platelet count was 150 × 103/mm3 for a diagnosis of cirrhosis. The sensitivity and specificity were 68.2% and 76.4%, respectively, for pathologic cirrhosis and 76.2% and 87.8%, respectively, for US cirrhosis. Forty‐eight percent of patients with HCC were thrombocytopenic. The proportion of thrombocytopenia was significantly greater in patients with HCV‐related HCC (63%) than in patients with HBV‐related HCC (42%). In the townships with high and low anti‐HCV prevalence, the prevalence of thrombocytopenia was 17.9% and 6.1%, respectively, (P < .001), respectively. Twenty‐five patients were diagnosed with HCC, and all of those patients resided in the high‐prevalence township.CONCLUSIONS.Thrombocytopenia was a valid surrogate of cirrhosis and a valid marker for the identification of individuals at high‐risk for HCC, especially in areas that had a high prevalence of HCV. Cancer 2006. © 2006 American Cancer Society.

show abstract

“…This may be due to the well-described paraneoplastic syndrome of thrombocytosis which occurs in 2.7% of HCCs. It is caused by tumors that secrete excessive amounts of thrombopoietin and is associated with larger tumor size and worse survival [32,33]. It is unclear why the survival advantage in patients with a platelet count below 100,000 per mm 3 is not seen in HIVinfected patients.…”

Section: Discussionmentioning

confidence: 99%